title: How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The use of iron supplementation to reduce ESA dosing in hemodialysis.
authors.affiliation: Winthrop-University Hospital, Mineola, New York.
authors.forename: Shayan
authors.initials: S
authors.lastname: Shirazian
authors.forename: Candace
authors.initials: C
authors.lastname: Grant
authors.forename: Ilene
authors.initials: I
authors.lastname: Miller
authors.forename: Steven
authors.initials: S
authors.lastname: Fishbane
mesh_terms: D018798:Anemia, Iron-Deficiency / Q000188:drug therapy*; D019587:Dietary Supplements; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage* / Q000378:metabolism; D006397:Hematinics / Q000008:administration & dosage*; D006801:Humans; D058085:Iron Compounds / Q000008:administration & dosage*; D011994:Recombinant Proteins / Q000008:administration & dosage; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000628:therapy*
chemical_list: C554270:EPO protein, human; D006397:Hematinics; D058085:Iron Compounds; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa